Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Apr-24 4:21 PM View:  | Terrillion Scott Sec'y; Chief Compliance & G.C. | Cara Therapeutics, Inc. (CARA) | 05-Apr-24 | Sale (Planned) | 2,753 | $0.83 | $2,284.99 | (3%) 91.0K to 88.25K | |
| 09-Apr-24 4:22 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 05-Apr-24 | Sale (Planned) | 2,753 | $0.83 | $2,284.99 | (5%) 56.12K to 53.37K | |
| 04-Mar-24 4:19 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 29-Feb-24 | Sale (Planned) | 5,834 | $0.89 | $5,192.26 | (3%) 186.35K to 180.52K | |
| 04-Mar-24 4:24 PM View: | Terrillion Scott Sec'y; Chief Compliance & G.C. | Cara Therapeutics, Inc. (CARA) | 29-Feb-24 | Sale (Planned) | 3,293 | $0.89 | $2,930.77 | (3%) 94.29K to 91.0K | |
| 04-Mar-24 4:13 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 29-Feb-24 | Sale (Planned) | 3,293 | $0.89 | $2,930.77 | (6%) 59.41K to 56.12K | |
| 12-Feb-24 5:10 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 08-Feb-24 | Sale (Planned) | 35,575 | $0.53 | $18,854.70 | (16%) 221.93K to 186.35K | |
| 05-Feb-24 4:34 PM View: | Terrillion Scott Sec'y; Chief Compliance & G.C. | Cara Therapeutics, Inc. (CARA) | 01-Feb-24 | Grant | 13,500 | -- | -- | 15% 88.56K to 102.06K | |
| 05-Feb-24 4:30 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 01-Feb-24 | Grant | 13,500 | -- | -- | 25% 53.68K to 67.18K | |
| 05-Feb-24 4:26 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 01-Feb-24 | Grant | 62,500 | -- | -- | 38% 164.41K to 226.91K | |
| 05-Feb-24 4:28 PM View: | Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D | Cara Therapeutics, Inc. (CARA) | 01-Feb-24 | Grant | 13,500 | -- | -- | 9% 153.75K to 167.25K | |
| 05-Feb-24 4:26 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 01-Feb-24 | Sale (Planned) | 4,981 | $0.55 | $2,739.55 | (2%) 226.91K to 221.93K | |
| 05-Feb-24 4:32 PM View: | Maynard Ryan D Chief Financial Officer | Cara Therapeutics, Inc. (CARA) | 01-Feb-24 | Grant | 13,500 | -- | -- | 100% 0 to 13.5K | |
| 03-Nov-23 4:37 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 02-Nov-23 | Sale (Planned) | 3,796 | $1.22 | $4,631.12 | (2%) 168.21K to 164.41K | |
| 04-Aug-23 5:21 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 03-Aug-23 | Sale (Planned) | 4,307 | $3.07 | $13,222.50 | (2%) 172.51K to 168.21K | |
| 27-Jun-23 4:08 PM View: | Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D | Cara Therapeutics, Inc. (CARA) | 23-Jun-23 | Sale (Planned) | 2,993 | $3.51 | $10,505.40 | (2%) 156.74K to 153.75K | |
| 27-Jun-23 4:09 PM View: | Terrillion Scott Sec'y; Chief Compliance & G.C. | Cara Therapeutics, Inc. (CARA) | 23-Jun-23 | Sale (Planned) | 2,483 | $3.51 | $8,715.33 | (3%) 91.05K to 88.56K | |
| 27-Jun-23 4:07 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 23-Jun-23 | Sale (Planned) | 2,723 | $3.51 | $9,557.73 | (5%) 56.4K to 53.68K | |
| 05-Jun-23 4:33 PM View: | Ives Jeffrey L. Director | Cara Therapeutics, Inc. (CARA) | 01-Jun-23 | Grant | 32,362 | -- | -- | 209% 15.48K to 47.84K | |
| 05-Jun-23 4:36 PM View: | von Moltke Lisa Director | Cara Therapeutics, Inc. (CARA) | 01-Jun-23 | Grant | 32,362 | -- | -- | 100% 0 to 32.36K | |
| 05-Jun-23 4:31 PM View: | Bains Harrison M Jr Director | Cara Therapeutics, Inc. (CARA) | 01-Jun-23 | Grant | 32,362 | -- | -- | 129% 25.08K to 57.44K | |
| 05-Jun-23 4:34 PM View: | Shiff Susan Ph.D. Director | Cara Therapeutics, Inc. (CARA) | 01-Jun-23 | Grant | 32,362 | -- | -- | 170% 19.08K to 51.44K | |
| 05-Jun-23 4:29 PM View: | Vogelbaum Martin Director | Cara Therapeutics, Inc. (CARA) | 01-Jun-23 | Grant | 64,724 | -- | -- | 144% 44.99K to 109.71K | |
| 09-May-23 4:22 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 05-May-23 | Sale (Planned) | 3,869 | $4.40 | $17,023.60 | (2%) 176.38K to 172.51K | |
| 06-Apr-23 5:14 PM View: | Terrillion Scott Sec'y; Chief Compliance & G.C. | Cara Therapeutics, Inc. (CARA) | 04-Apr-23 | Sale (Planned) | 2,481 | $4.91 | $12,181.70 | (3%) 93.53K to 91.05K | |
| 06-Apr-23 5:13 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 04-Apr-23 | Sale (Planned) | 2,481 | $4.91 | $12,181.70 | (4%) 58.88K to 56.4K | |
| 06-Apr-23 5:12 PM View: | Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D | Cara Therapeutics, Inc. (CARA) | 04-Apr-23 | Sale (Planned) | 2,733 | $4.91 | $13,419.00 | (2%) 159.47K to 156.74K | |
| 07-Mar-23 4:44 PM View: | Terrillion Scott Sec'y; Chief Compliance & G.C. | Cara Therapeutics, Inc. (CARA) | 03-Mar-23 | Sale (Planned) | 6,256 | $9.71 | $60,745.80 | (6%) 99.78K to 93.53K | |
| 07-Mar-23 4:47 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 03-Mar-23 | Sale (Planned) | 5,987 | $9.71 | $58,133.80 | (3%) 182.37K to 176.38K | |
| 07-Mar-23 4:43 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 03-Mar-23 | Sale (Planned) | 6,221 | $9.71 | $60,405.90 | (10%) 65.11K to 58.88K | |
| 07-Mar-23 4:46 PM View: | Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D | Cara Therapeutics, Inc. (CARA) | 03-Mar-23 | Sale (Planned) | 6,802 | $9.71 | $66,047.40 | (4%) 166.28K to 159.47K | |
| 17-Feb-23 4:27 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 16-Feb-23 | Sale (Planned) | 2,265 | $10.20 | $23,103.00 | (3%) 67.37K to 65.11K | |
| 12-Feb-24 5:15 PM View: | Maynard Ryan D Chief Financial Officer | Cara Therapeutics, Inc. (CARA) | 08-Feb-23 | Sale (Planned) | 5,488 | $0.53 | $2,908.64 | (41%) 13.5K to 8.01K | |
| 12-Feb-24 5:16 PM View: | Terrillion Scott Sec'y; Chief Compliance & G.C. | Cara Therapeutics, Inc. (CARA) | 08-Feb-23 | Sale (Planned) | 7,770 | $0.53 | $4,118.10 | (8%) 102.06K to 94.29K | |
| 12-Feb-24 5:13 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 08-Feb-23 | Sale (Planned) | 7,770 | $0.53 | $4,118.10 | (12%) 67.18K to 59.41K | |
| 03-Feb-23 6:38 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 02-Feb-23 | Market Sale (Planned) | 4,191 | $11.80 | $49,453.80 | (2%) 186.56K to 182.37K | (3%) |
| 19-Jan-23 4:18 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 17-Jan-23 | Market Sale (Planned) | 2,265 | $10.81 | $24,484.70 | (3%) 69.64K to 67.37K | (12%) |
| 03-Jan-23 4:32 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 29-Dec-22 | Sale (Planned) | 2,265 | $10.18 | $23,057.70 | (3%) 71.9K to 69.64K | |
| 23-Dec-22 4:54 PM View: | Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D | Cara Therapeutics, Inc. (CARA) | 21-Dec-22 | Market Sale (Planned) | 3,506 | $11.27 | $39,512.60 | (2%) 169.78K to 166.28K | (8%) |
| 23-Dec-22 4:52 PM View: | Terrillion Scott Sec'y; Chief Compliance & G.C. | Cara Therapeutics, Inc. (CARA) | 21-Dec-22 | Market Sale (Planned) | 2,561 | $11.27 | $28,862.50 | (3%) 102.34K to 99.78K | (8%) |
| 23-Dec-22 4:53 PM View: | Goncalves Joana Chief Medical Officer | Cara Therapeutics, Inc. (CARA) | 21-Dec-22 | Market Sale (Planned) | 2,992 | $11.27 | $33,719.80 | (4%) 74.89K to 71.9K | (8%) |
| 18-Nov-22 5:23 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 16-Nov-22 | Market Sale (Planned) | 14,470 | $11.13 | $161,051.00 | (7%) 201.03K to 186.56K | (9%) |
| 16-Sep-22 4:21 PM View: | Vogelbaum Martin Director | Cara Therapeutics, Inc. (CARA) | 14-Sep-22 | Sale | 10,800 | $10.28 | $111,024.00 | (19%) 55.79K to 44.99K | |
| 19-Jul-22 5:13 PM View: | Bains Harrison M Jr Director | Cara Therapeutics, Inc. (CARA) | 15-Jul-22 | Sale (Planned) | 7,200 | $9.05 | $65,160.00 | (22%) 32.28K to 25.08K | |
| 19-Jul-22 5:16 PM View: | Ives Jeffrey L. Director | Cara Therapeutics, Inc. (CARA) | 15-Jul-22 | Sale (Planned) | 3,600 | $9.05 | $32,580.00 | (19%) 19.08K to 15.48K | |
| 16-Jun-22 5:14 PM View: | Makara Richard VP, Head of Accting;Controller | Cara Therapeutics, Inc. (CARA) | 15-Jun-22 | Grant | 7,500 | -- | -- | 123% 6.08K to 13.58K | |
| 06-Jun-22 5:50 PM View: | Bains Harrison M Jr Director | Cara Therapeutics, Inc. (CARA) | 02-Jun-22 | Grant | 11,876 | -- | -- | 58% 20.4K to 32.28K | |
| 06-Jun-22 5:49 PM View: | Vogelbaum Martin Director | Cara Therapeutics, Inc. (CARA) | 02-Jun-22 | Grant | 35,628 | -- | -- | 177% 20.16K to 55.79K | |
| 06-Jun-22 5:51 PM View: | Ives Jeffrey L. Director | Cara Therapeutics, Inc. (CARA) | 02-Jun-22 | Grant | 11,876 | -- | -- | 165% 7.2K to 19.08K | |
| 06-Jun-22 5:52 PM View: | Shiff Susan Ph.D. Director | Cara Therapeutics, Inc. (CARA) | 02-Jun-22 | Grant | 11,876 | -- | -- | 165% 7.2K to 19.08K | |
| 05-Apr-22 5:48 PM View: | Posner Christopher President and CEO Director | Cara Therapeutics, Inc. (CARA) | 04-Apr-22 | Market Sale (Planned) | 2,006 | $12.67 | $25,416.00 | (< 1%) 203.04K to 201.03K | 4% |
